# Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

> **NCT05617963** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 100 (estimated)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05617963
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-24
- **Primary completion:** 2028-02-24
- **Final completion:** 2030-02-24
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05617963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05617963, "Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05617963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*